{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:32:42Z","timestamp":1775025162050,"version":"3.50.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon entity that, in contrast to classical Hodgkin lymphoma (cHL), universally expresses CD20, a hallmark of the disease. The majority of the patients present with early-stage disease, and treatment with local radiation provides excellent disease control and overall survival (OS). For locally extensive or advanced stages, paradigms used for cHL have been employed, with similar outcomes. Unlike cHL, late relapses may occur, as well as a propensity to transform to an aggressive B-cell non-Hodgkin lymphoma that underscores the importance of long-term follow-up and rebiopsy at the time of relapse. Deaths caused by NLPHL are uncommon, and in older series, secondary malignancies and other treatment-related toxicities contributed appreciably to overall mortality. Expression of CD20 in NLPHL has led to the evaluation of rituximab as a therapeutic option. Although results with single-agent rituximab in the front-line setting are inferior to conventional therapy, rituximab is a reasonable choice for relapsed disease because of the high overall response rate and excellent tolerability. Most patients have a long OS; therefore, overall goals of therapy should be to minimize the risk for relapse and long-term toxicity.<\/jats:p>","DOI":"10.1182\/blood-2013-07-453241","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T07:18:09Z","timestamp":1383981489000},"page":"4182-4188","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["How I treat nodular lymphocyte predominant Hodgkin lymphoma"],"prefix":"10.1182","volume":"122","author":[{"given":"Ranjana H.","family":"Advani","sequence":"first","affiliation":[{"name":"Medical Oncology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Stanford University Medical Center, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"3","key":"2019111817154674400_B1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease.","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111817154674400_B2","author":"Stein"},{"issue":"Suppl 1","key":"2019111817154674400_B3","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1038\/modpathol.2012.182","article-title":"Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications.","volume":"26","author":"Harris","year":"2013","journal-title":"Mod Pathol"},{"issue":"5","key":"2019111817154674400_B4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00000478-199405000-00014","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease. A distinct clinicopathological entity.","volume":"18","author":"Mason","year":"1994","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2019111817154674400_B5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.23367","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma with non-invasive or early invasive growth pattern suggests an early step of the disease with a highly favorable outcome","volume":"88","author":"Carbone","year":"2013","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111817154674400_B6","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1182\/blood-2003-02-0626","article-title":"Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell\/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell\/histiocyte-rich B-cell lymphoma.","volume":"102","author":"Boudov\u00e1","year":"2003","journal-title":"Blood"},{"issue":"23","key":"2019111817154674400_B7","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development.","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"2019111817154674400_B8","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.V84.10.3291.3291","article-title":"Lymphocyte predominance Hodgkin\u2019s disease: lineage and clonality determination using a single-cell assay.","volume":"84","author":"Delabie","year":"1994","journal-title":"Blood"},{"issue":"7","key":"2019111817154674400_B9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199708143370703","article-title":"Origin of nodular lymphocyte-predominant Hodgkin\u2019s disease from a clonal expansion of highly mutated germinal-center B cells [see comments].","volume":"337","author":"Marafioti","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111817154674400_B10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3324\/haematol.2009.010157","article-title":"Mutations in the genes coding for the NF-\u03baB regulating factors I\u03baB\u03b1 and A20 are uncommon in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma.","volume":"95","author":"Schumacher","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111817154674400_B11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2011-03-341560","article-title":"Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma.","volume":"118","author":"Saarinen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111817154674400_B12","first-page":"1889","article-title":"European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.","volume":"96","author":"Anagnostopoulos","year":"2000","journal-title":"Blood"},{"key":"2019111817154674400_B13","article-title":"Hodgkin lymphoma.","author":"Stein"},{"issue":"5","key":"2019111817154674400_B14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2559.2011.03829.x","article-title":"CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma.","volume":"58","author":"Venkataraman","year":"2011","journal-title":"Histopathology"},{"issue":"2","key":"2019111817154674400_B15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/blood.V88.2.657.bloodjournal882657","article-title":"Nodular lymphocyte-predominant Hodgkin\u2019s disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction.","volume":"88","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"6","key":"2019111817154674400_B16","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V86.6.2312.bloodjournal8662312","article-title":"Clonal relationship between lymphocytic predominance Hodgkin\u2019s disease and concurrent or subsequent large-cell lymphoma of B lineage.","volume":"86","author":"Wickert","year":"1995","journal-title":"Blood"},{"issue":"3","key":"2019111817154674400_B17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/bjh.12055","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents\u2014a comprehensive review of biology, clinical course and treatment options.","volume":"159","author":"Shankar","year":"2012","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111817154674400_B18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/JCO.2012.43.5958","article-title":"High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma.","volume":"31","author":"Saarinen","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111817154674400_B19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin Study Group.","volume":"26","author":"Nogov\u00e1","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111817154674400_B20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma.","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111817154674400_B21","first-page":"482","article-title":"Position emission tomography with or without computed tomography in the primary staging of Hodgkin\u2019s lymphoma.","volume":"91","author":"Hutchings","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2019111817154674400_B22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.11661","article-title":"18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin\u2019s disease.","volume":"93","author":"Ansquer","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"2019111817154674400_B23","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","article-title":"Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"2019111817154674400_B24","volume-title":"Hodgkin's Disease and Allied Disorders","author":"Jackson","year":"1947"},{"issue":"3","key":"2019111817154674400_B25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2141.2012.09067.x","article-title":"Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.","volume":"157","author":"Porrata","year":"2012","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"2019111817154674400_B26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/13.S1.44","article-title":"Workshop on the relationship between nodular lymphocyte predominant Hodgkin\u2019s lymphoma and T cell\/histiocyte-rich B cell lymphoma.","volume":"13","author":"R\u00fcdiger","year":"2002","journal-title":"Ann Oncol"},{"issue":"8","key":"2019111817154674400_B27","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/1042819031000149421","article-title":"Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.","volume":"45","author":"Huang","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111817154674400_B28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"2019111817154674400_B29","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte predominant Hodgkin lymphoma.","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111817154674400_B30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0167-8140(84)80001-8","article-title":"Lymphocyte predominant Hodgkin\u2019s disease: clinical presentation and results of treatment.","volume":"1","author":"Russell","year":"1984","journal-title":"Radiother Oncol"},{"issue":"7","key":"2019111817154674400_B31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma.","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111817154674400_B32","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","article-title":"Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).","volume":"16","author":"Nogov\u00e1","year":"2005","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111817154674400_B33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin\u2019s disease.","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"issue":"1","key":"2019111817154674400_B34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin\u2019s lymphoma: patient outcomes from a large, single-institution series with long follow-up.","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111817154674400_B35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"2019111817154674400_B36","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0025-7125(16)33107-8","article-title":"The treatment of Hodgkin\u2019s disease.","volume":"50","author":"Kaplan","year":"1966","journal-title":"Med Clin North Am"},{"issue":"3","key":"2019111817154674400_B37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines.","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"2019111817154674400_B38","article-title":"Modern radiotherapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG).","volume-title":"Int J Radiat Oncol Biol Phys","author":"Specht"},{"key":"2019111817154674400_B39"},{"issue":"Suppl 6","key":"2019111817154674400_B40","doi-asserted-by":"crossref","first-page":"vi55","DOI":"10.1093\/annonc\/mdr378","article-title":"Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"22","author":"Eichenauer","year":"2011","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111817154674400_B41","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ijrobp.2008.09.049","article-title":"Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin\u2019s lymphoma.","volume":"74","author":"Haas","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2019111817154674400_B42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.","volume":"110","author":"Mauz-K\u00f6rholz","year":"2007","journal-title":"Cancer"},{"key":"2019111817154674400_B43","author":"Appel"},{"key":"2019111817154674400_B44","author":"Wilder"},{"issue":"17","key":"2019111817154674400_B45","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111817154674400_B46","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ejca.2011.10.018","article-title":"Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin\u2019s lymphoma - an Anglo-French collaborative report.","volume":"48","author":"Shankar","year":"2012","journal-title":"Eur J Cancer"},{"issue":"26","key":"2019111817154674400_B47","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma\u2014a report from the Children\u2019s Oncology Group.","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111817154674400_B48","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"2019111817154674400_B49","author":"Xing"},{"issue":"1","key":"2019111817154674400_B50","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/JCO.2009.26.3293","article-title":"What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin\u2019s lymphoma?","volume":"28","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111817154674400_B51","author":"Fanale"},{"issue":"11","key":"2019111817154674400_B52","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111817154674400_B53","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/COC.0b013e318145b9db","article-title":"Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.","volume":"30","author":"Chera","year":"2007","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"2019111817154674400_B54","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2013.03.008","article-title":"High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.","volume":"19","author":"Karuturi","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111817154674400_B55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3061.3061","article-title":"High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) for lymphocyte predominant Hodgkin\u2019s disease [abstract].","volume":"108","author":"Bierman","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111817154674400_B56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000341562","article-title":"Rituximab plus ifosfamide, carboplatin and etoposide for T-cell\/histiocyte-rich B-cell lymphoma arising in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma.","volume":"5","author":"Park","year":"2012","journal-title":"Case Rep Oncol"},{"issue":"1","key":"2019111817154674400_B57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2007-03-078725","article-title":"Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).","volume":"111","author":"Schulz","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111817154674400_B58","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/26\/4182\/1372367\/4182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/122\/26\/4182\/1372367\/4182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T16:56:13Z","timestamp":1596819373000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/122\/26\/4182\/32352\/How-I-treat-nodular-lymphocyte-predominant-Hodgkin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,19]]},"references-count":58,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2013,12,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-07-453241","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,19]]}}}